Navigation Links
Statement by the Scientific Advisory Board of the Patient Advocate Foundation/National Patient Advocate Foundation on Changes to the USPSTF Mammography Guidelines
Date:11/20/2009

WASHINGTON, Nov. 20 /PRNewswire-USNewswire/ -- Patient Advocate Foundation (PAF) is a national, non-profit organization that provides case management services to patients diagnosed with chronic, life-threatening and debilitating diseases. Last year, PAF served 48,369 patients and responded to an additional 9.5 million contacts for information. PAF's companion organization, the National Patient Advocate Foundation (NPAF), is a national, non-profit organization dedicated to the mission of creating avenues of improved patient access to health care through public policy reform at the state and federal levels. The advocacy activities and policy positions of NPAF are informed and influenced by the experience of patients who are served by PAF. The PAF/NPAF Scientific Advisory Board has reviewed the recommendations released by the U.S. Preventive Services Task Force (USPSTF) on screening for breast cancer.

While reasonable individuals can come to different conclusions, PAF/NPAF must respectfully disagree with the recently revised recommendations released by the U.S. Preventive Services Task Force. Even though the USPSTF recommendations are for women of average risk, we nonetheless find the potential effects of its recommendations to be troubling. While the Task Force does not establish government policy, we are concerned that private health insurance companies could make coverage decisions based on these recommendations. "In 2008, breast cancer was the leading cancer diagnosis of PAF patients. Of those, 25% of all PAF breast cancer patients were between the ages of 40-49 and would be directly affected by these recommendations," stated Nancy Davenport-Ennis, CEO of PAF/NPAF.

The Task Force did not attach great strength to the evidence for its recommendation and noted that mammography would reduce the risk of death from breast cancer by 15 percent both in women in their forties and in women in their fifties, but chose not to recommend annual screening for women in their forties because it would save marginally fewer lives and is associated with more procedures. Moreover, a table in the report clearly shows a meta-analysis favoring screening for women from 40-49 years of age. "Recommendations as important as these should not be decided on narrow evidence that is not widely supported by the breast cancer and provider community," stated Robert Rifkin, M.D., Chair, PAF/NPAF Scientific Advisory Board. Until there is much more conclusive evidence, we continue to join our non-profit colleagues, including the American Cancer Society, Susan G. Komen Foundation, National Comprehensive Cancer Network, and the American Medical Association, in recommending that women over the age of 40 continue regular, annual mammography screening.

"We believe that a measured approach is to continue screening women of standard cancer risk between the ages of 40 and 49 with annual mammography, and to work to improve the accuracy of screening for breast cancer," stated Dennis Gastineau, M.D., Scientific Liaison to the Executive Board of Directors.

For more information see www.npaf.org and www.patientadvocate.org.

SOURCE National Patient Advocate Foundation


'/>"/>
SOURCE National Patient Advocate Foundation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Statement of Eli Lilly and Company on Dr. David Egilman Settlement:
2. Takeda statement on ACTOS meta-analysis published in the Journal of the American Medical Association
3. Takeda Statement on ACTOS(R) (Pioglitazone HCl) Meta-Analysis Published in the Journal of the American Medical Association
4. Statement by Mike Leavitt Secretary of Health and Human Services on the United States-China Bilateral Meetings on Food and Drug Safety
5. Statement by Oscar S. Wyatt, Jr.
6. Statement from Employment Policies Institute on Senator Hillary Clintons Health Care Plan
7. Pelosi Statement on Proposed Entitlement Task Force
8. Statement by Robert Greenstein, Executive Director of the Center on Budget and Policy Priorities, on the New Congressional SCHIP Agreement
9. Statement on House/Senate Agreement on SCHIP Legislation
10. Statement from the Alliance for Quality Nursing Home Care
11. Produce for Better Health Foundation Releases Statement on Study Saying Fruit & Vegetable Consumption Not Strongly Associated With Colon Cancer Risk
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the ... In terms of the latter, setting the bar too high can result in disappointment, ... just slow progress toward their goal. , Research from PsychTests.com reveals ...
(Date:6/24/2016)... , ... June 24, 2016 , ... June 19, 2016 ... dangers associated with chronic pain and the benefits of holistic treatments, Serenity Recovery ... are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced that ... chosen by their peers for this recognition are considered among the top 2 percent ... special honors as members of this year’s Legal Elite Hall of Fame: Miami ...
(Date:6/24/2016)... ... ... Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a Fair ... hour by 2020 and then adjusting it yearly to increase at the same rate as ... the wage floor does not erode again, and make future increases more predictable. , The ...
(Date:6/24/2016)... York, NY (PRWEB) , ... June 24, 2016 ... ... publication Haute Living, is proud to recognize Dr. Barry M. Weintraub as a ... that “the most beautiful women in the world, and the most handsome men, ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... the "Pharmaceutical Excipients Market by Type (Organic Chemical ... Preservative), Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast ... The global pharmaceutical excipients ... 2021 at a CAGR of 6.1% in the forecast ...
(Date:6/23/2016)... June 23, 2016 Research and Markets ... Medical Market Analysis 2016 - Forecast to 2022" report ... The report contains up to date financial data derived from ... of major trends with potential impact on the market during ... market segmentation which comprises of sub markets, regional and country ...
(Date:6/23/2016)... -- Bracket , a leading clinical trial technology and ... platform, Bracket eCOA (SM) 6.0, at the 52 nd ... 2016 in Philadelphia , Pennsylvania.  A demonstration ... of its kind to fully integrate with RTSM, will be ... is a flexible platform for electronic clinical outcomes assessments that ...
Breaking Medicine Technology: